Daiwa Securities Group
RXRX icon

Daiwa Securities Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Daiwa Securities Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6K Buy
+15,500
New +$59.9K ﹤0.01% 1137

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Daiwa Securities Group's RXRX Position: Q1 2026 in Review

Daiwa Securities Group increased its Recursion Pharmaceuticals (RXRX) stake by 805% in Q1 2026, buying an estimated $53.3K and bringing the position to 15,500 shares worth $47.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Daiwa Securities Group first reported a position in RXRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $116K in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Daiwa Securities Group held 15,500 shares of Recursion Pharmaceuticals worth $47.6K as of Q1 2026.
  • Daiwa Securities Group bought 13,788 Recursion Pharmaceuticals shares in Q1 2026, an estimated $53.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #1110 holding.
  • Daiwa Securities Group first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Daiwa Securities Group's Recursion Pharmaceuticals position peaked at $116K in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.